论文部分内容阅读
嗜铬细胞瘤的临床诊断一般不难作出,但在肿瘤的定位诊断,尤其在肾上腺外的、多发的或恶性播散性肿瘤,有时仍较为困难。恶性肿瘤在手术无法切除时,其治疗也尚无特效方法。 1980年美国密执安大学医学实验中心Wieland等合成间位碘代苄胺(MIBG),并证实其能使动物肾上腺髓质显象。此后,该药物即被应用于嗜铬细胞瘤的定位诊断和对无法手术的恶性肿瘤治疗,并取得显著效果。从而使非创伤性方法诊断嗜铬细胞瘤的准确性进一步提高,并对恶性嘻铬细胞瘤的治疗开辟了一条新的途径。
The clinical diagnosis of pheochromocytoma is not difficult to make, but it is sometimes difficult to locate the tumor, especially in extraadrenal, multiple or malignant disseminated tumors. Malignant tumors have no special treatment for their treatment when they cannot be removed. In 1980, Wieland et al., of the University of Michigan Medical Experiment Center, synthesized meta-iodobenzylamine (MIBG) and confirmed its ability to display adrenal medulla in animals. Since then, the drug has been applied to the diagnosis of pheochromocytoma and the treatment of inoperable malignant tumors, and has achieved remarkable results. Therefore, the accuracy of non-invasive methods for the diagnosis of pheochromocytoma is further improved, and a new approach has been opened for the treatment of malignant chromyocytoma.